📄El estudio, “Antagonista receptor de mineralocorticoide de vamorolone: evidencia de los ensayos clínicos LIONHEART y VISION-DMD,” se publicó en la revista Steroids.
🔗Lee el artículo completo en el siguiente link: lnkd.in/efrHDjET
#TheAkariFoundation #DistrofiaMuscularDeDuchenne #Agamree
Health Canada Grants Approval for AGAMREE® as First Cure for Duchenne Muscular Dystrophy #Canada #Mississauga #Duchenne #AGAMREE #Kye_Pharmaceuticals
Agamree to be sold in United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain starting in 2026 Santhera Pharmaceuticals announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
Agamree to be sold in United Arab Emirates, Saudi Arabia, Kuwait, Oman and Bahrain starting in 2026
#agamree #vamorolone #uae #bahrain #oman #saudi_arabia #kuwait
👉 Read More: DMDWarrioR.com
Agamree (vamorolone) will be Covered in Slovenia by the Slovenian Health Insurance Fund
The drug will be covered by the Slovenian Health Insurance Fund as of April 23, 2025.
#dmd #duchenne #agamree #vamorolone #Slovenia
Health Canada Accepts Priority Review for AGAMREE® to Treat Duchenne Muscular Dystrophy #Canada #Mississauga #Duchenne_Muscular_Dystrophy #AGAMREE #Kye_Pharmaceuticals
NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera AGAMREE (vamorolone) has been recommended for use in the National Health Service (NHS) in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 and up by the National Institute for Health and Care Excellence (NICE), according to Santhera Pharmaceuticals.
NICE Final Guidance for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy Is Positive for Santhera
👉 Read More: dmdwarrior.com
#dmd #duchenne #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #agamree #vamorolone #santhera #NICE #uk #england #wales #northernireland
Vamorolone (Agamree) Approved in Scotland The Scottish Medicines Consortium (SMC) approved the Agamree (Vamorolone) for use by NHS Scotland. The medication vamorolone, also marketed under the brand name Agamree, has been approved by the Scottish Medicines Consortium (SMC) as a therapy option for Duchenne muscular dystrophy in patients four years of age and older in Scotland as of today, Monday, January 13 2025.
Vamorolone (Agamree) Approved in Scotland
👉 Read More: dmdwarrior.com
#dmd #duchenne #bmd #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneawareness #duchenneheroes #musculardystrophy #gene #dna #agamree #vamorolone #santhera #scotland #uk #england
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group "We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. ” said Julie Gosper, Senior Vice President, Europe and Partner Markets at Clinigen. Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. Santhera Pharmaceuticals and Clinigen Group announce that they have signed a Supply and Distribution Agreement for AGAMREE in countries where the product can currently not be commercially obtained via Santhera or one of its current distribution partners. The agreement will enable access to AGAMREE on a case-by-case basis for patients with Duchenne muscular dystrophy (DMD) in situations where the treating physician deems there to be no suitable alternatives and where regulations allow for it. This agreement allows Santhera to receive the majority share of revenue generated from the supply of product in these additional countries.
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group
👉 Read More: dmdwarrior.com
#dmd #duchenne #bmd #becker #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenne #agamree #vamorolone #santhera #Clinigen #clinigengroup
Agamree recommended for NHS use in England
Agamree recommended for NHS use in England
Agamree recommended for NHS use in England
Agamree recommended for NHS use in England
Agamree recommended for NHS use in England 🎉
Elsewhere, Agamree was approved in China, making it the country’s first treatment for DMD.
#dmd #duchenne #bmd #becker #santhera #agamree #uk #vamorolone #england
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy 🎉
Source: www.santhera.com/assets/files...
#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #santhera #agamree #china #vamorolone
